Answers are grounded in this paper and cite their sources.
Progressive neuronal degeneration is one of the symptoms of neurodegenerative diseases (NDDs), which often cause cognitive and physical impairments. In order to start therapy before clinical symptoms appear and to limit the progression of diseases like Parkinson's disease (PD) and Alzheimer's disease (AD), early screening and diagnosis are crucial. Finding new, accurate and reliable biomarkers is a key objective in recent research in order to facilitate early diagnosis and offer insights into the progression of disease. Compared with invasive, complex, and costly cerebrospinal fluid (CSF) screening methods, salivary analysis has emerged as a promising approach for identifying biomarkers and matrices relevant to assessing NDDs. Compared to other often examined biofluids, saliva collection offers a number of benefits due to its accessibility, non-invasiveness, and suitability for recurrent sampling. These characteristics facilitate early diagnosis and timely treatment of diseases. Current research indicates that β-amyloid (Aβ), tau protein, alpha synuclein (α-syn), DJ-1, and several miRNAs in saliva show potential as biomarkers for neurodegenerative diseases. This narrative review addresses the growing need for reliable and standardized saliva-based biomarkers by integrating evidence on biomarker performance with methodological challenges, emerging technologies, and innovative perspectives on multimarker panels, standardization, and validation to facilitate their clinical translation in Alzheimer’s and Parkinson’s diseases.
No takes yet. Share an insight, caveat, or question.
Basirat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: